文献速递头颈部肿瘤放疗姑息放疗与转移瘤

头颈癌放疗后慢性阿片类药物使用风险的系统综述与荟萃分析

Risk of Chronic Opioid Use After Radiation for Head and Neck Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · Adv Radiat Oncol · 2020-10-26

该系统综述与荟萃分析纳入7项回顾性研究共1841例接受根治性放疗或放化疗的头颈癌患者,评估慢性阿片类药物使用(COU)的患病率及危险因素。结果显示放疗后3个月COU比例为40.7%(95%CI:22.6%-61.7%),6个月为15.5%(95%CI:7.3%-29.7%)。口咽原发、精神疾病史、酒精滥用史及放疗前阿片类药物需求是COU的高危因素。

要点

  • 头颈癌根治性放疗后3个月COU比例为40.7%,6个月降至15.5%。
  • 口咽原发肿瘤COU率最高,为46.6%(95%CI:30.8%-63.1%)。
  • 精神疾病史、酒精滥用史及放疗前阿片使用是COU高危因素。

核心结论

  • 相当比例的头颈癌根治性放疗患者存在慢性阿片类药物使用,口咽原发、精神疾病史、酒精滥用史及放疗前阿片需求为高危因素,需新策略加以干预。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed(Medline)、EMBASE和Cochrane Library数据库自建库至2020年1月,纳入7项回顾性研究共1841例接受根治性放疗或放化疗的头颈癌患者。

主要发现

  • 放疗后3个月COU比例为40.7%(95%CI:22.6%-61.7%;I2=97.1%),6个月为15.5%(95%CI:7.3%-29.7%;I2=94.3%)。
  • 按原发部位,口咽恶性肿瘤COU率最高,为46.6%(95%CI:30.8%-63.1%;P<.0001)。
  • 有精神疾病史者COU比例为61.7%,既往或当前酒精滥用者为53.9%,放疗前有阿片需求者为51.6%(P=.035)。
  • 患者中位年龄59.4岁(范围56.0-62.0),男性1343例(72.9%),女性498例(27.1%)。

临床怎么用

  • 对头颈癌放疗患者应常规评估精神疾病史、酒精滥用史及放疗前阿片使用情况,识别COU高危人群并及早干预。

局限性

  • 纳入研究均为回顾性研究,异质性高(I2最高达97.1%),可能影响合并结果的稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Opioid addiction is a major public health concern. Chronic opioid use (COU) patterns after radiation for head and neck cancer (HNC) remain poorly understood. The aim of this study was to estimate the prevalence of COU and to identify its risk factors in patients with HNC undergoing curative-intent radiation therapy (RT) or chemoradiotherapy (CRT). METHODS AND MATERIALS: We performed a systematic review and meta-analysis using the PubMed (Medline), EMBASE, and Cochrane Library databases, queried from dates of inception until January 2020. COU was defined as persistent use of opioids ≥ 3 months after treatment completion. Meta-analyses were performed using random effects models. Heterogeneity was assessed using the I2 value. RESULTS: Seven retrospective studies, reporting on 1841 patients, met the inclusion criteria. Median age was 59.4 (range: 56.0-62.0) years with 1343 (72.9%) men and 498 (27.1%) women. Primary tumor locations included oropharynx (n = 891, 48.4%), oral cavity (n = 533, 29.0%), larynx (n = 93, 5.1%), hypopharynx (n = 32, 1.7%), and nasopharynx (n = 29, 1.6%). Eight hundred fifty-four (46.0%) patients had stage I/II and 952 (50.3%) had stage III-IV disease. Three hundred one (16.3%) patients had RT alone, 738 (40.1%) received CRT, and 594 (32.3%) underwent surgery followed by adjuvant RT/CRT. The proportion of patients with HNC who developed COU post-RT/CRT was 40.7% at 3 months (95% confidence interval [CI]: 22.6%-61.7%; I2 = 97.1%) and 15.5% at 6 months (95% CI: 7.3%-29.7%; I2 = 94.3%). Oropharyngeal malignancies had the highest rate of COU based on primary tumor location (46.6%; 95% CI: 30.8%-63.1%; P < .0001). High proportions of COU were found in patients with a history of psychiatric disorder(s) (61.7%), former/current alcohol abuse (53.9%), and opioid requirements before radiation treatment (51.6%; P = .035). CONCLUSIONS: A significant proportion of patients who undergo RT for HNC suffer from COU. High-risk factors for COU include an oropharyngeal primary, history of psychiatric disorder, former/current alcohol abuse, and pre-treatment opioid use. New strategies to mitigate COU are needed.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zayed S, Lin C, Boldt RG, et al. Risk of Chronic Opioid Use After Radiation for Head and Neck Cancer: A Systematic Review and Meta-Analysis. Adv Radiat Oncol. 2020. PMID: 33728386. doi:10.1016/j.adro.2020.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。